Novel myostatin-specific antibody enhances muscle strength in muscle disease models
Abstract Myostatin, a member of the transforming growth factor-β superfamily, is an attractive target for muscle disease therapy because of its role as a negative regulator of muscle growth and strength. Here, we describe a novel antibody therapeutic approach that maximizes the potential of myostati...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/f5532204ebd94faaa523b4801829ed1c |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:f5532204ebd94faaa523b4801829ed1c |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:f5532204ebd94faaa523b4801829ed1c2021-12-02T10:47:54ZNovel myostatin-specific antibody enhances muscle strength in muscle disease models10.1038/s41598-021-81669-82045-2322https://doaj.org/article/f5532204ebd94faaa523b4801829ed1c2021-01-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-81669-8https://doaj.org/toc/2045-2322Abstract Myostatin, a member of the transforming growth factor-β superfamily, is an attractive target for muscle disease therapy because of its role as a negative regulator of muscle growth and strength. Here, we describe a novel antibody therapeutic approach that maximizes the potential of myostatin-targeted therapy. We generated an antibody, GYM329, that specifically binds the latent form of myostatin and inhibits its activation. Additionally, via “sweeping antibody technology”, GYM329 reduces or “sweeps” myostatin in the muscle and plasma. Compared with conventional anti-myostatin agents, GYM329 and its surrogate antibody exhibit superior muscle strength-improvement effects in three different mouse disease models. We also demonstrate that the superior efficacy of GYM329 is due to its myostatin specificity and sweeping capability. Furthermore, we show that a GYM329 surrogate increases muscle mass in normal cynomolgus monkeys without any obvious toxicity. Our findings indicate the potential of GYM329 to improve muscle strength in patients with muscular disorders.Hiroyasu MuramatsuTaichi KuramochiHitoshi KatadaAtsunori UeyamaYoshinao RuikeKen OhmineMeiri Shida-KawazoeRie Miyano-NishizawaYuichiro ShimizuMomoko OkudaYuji HoriMadoka HayashiKenta HarayaNobuhiro BanTatsuya NonakaMasaki HondaHidetomo KitamuraKunihiro HattoriTakehisa KitazawaTomoyuki IgawaYoshiki KawabeJunichi NezuNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-16 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Hiroyasu Muramatsu Taichi Kuramochi Hitoshi Katada Atsunori Ueyama Yoshinao Ruike Ken Ohmine Meiri Shida-Kawazoe Rie Miyano-Nishizawa Yuichiro Shimizu Momoko Okuda Yuji Hori Madoka Hayashi Kenta Haraya Nobuhiro Ban Tatsuya Nonaka Masaki Honda Hidetomo Kitamura Kunihiro Hattori Takehisa Kitazawa Tomoyuki Igawa Yoshiki Kawabe Junichi Nezu Novel myostatin-specific antibody enhances muscle strength in muscle disease models |
| description |
Abstract Myostatin, a member of the transforming growth factor-β superfamily, is an attractive target for muscle disease therapy because of its role as a negative regulator of muscle growth and strength. Here, we describe a novel antibody therapeutic approach that maximizes the potential of myostatin-targeted therapy. We generated an antibody, GYM329, that specifically binds the latent form of myostatin and inhibits its activation. Additionally, via “sweeping antibody technology”, GYM329 reduces or “sweeps” myostatin in the muscle and plasma. Compared with conventional anti-myostatin agents, GYM329 and its surrogate antibody exhibit superior muscle strength-improvement effects in three different mouse disease models. We also demonstrate that the superior efficacy of GYM329 is due to its myostatin specificity and sweeping capability. Furthermore, we show that a GYM329 surrogate increases muscle mass in normal cynomolgus monkeys without any obvious toxicity. Our findings indicate the potential of GYM329 to improve muscle strength in patients with muscular disorders. |
| format |
article |
| author |
Hiroyasu Muramatsu Taichi Kuramochi Hitoshi Katada Atsunori Ueyama Yoshinao Ruike Ken Ohmine Meiri Shida-Kawazoe Rie Miyano-Nishizawa Yuichiro Shimizu Momoko Okuda Yuji Hori Madoka Hayashi Kenta Haraya Nobuhiro Ban Tatsuya Nonaka Masaki Honda Hidetomo Kitamura Kunihiro Hattori Takehisa Kitazawa Tomoyuki Igawa Yoshiki Kawabe Junichi Nezu |
| author_facet |
Hiroyasu Muramatsu Taichi Kuramochi Hitoshi Katada Atsunori Ueyama Yoshinao Ruike Ken Ohmine Meiri Shida-Kawazoe Rie Miyano-Nishizawa Yuichiro Shimizu Momoko Okuda Yuji Hori Madoka Hayashi Kenta Haraya Nobuhiro Ban Tatsuya Nonaka Masaki Honda Hidetomo Kitamura Kunihiro Hattori Takehisa Kitazawa Tomoyuki Igawa Yoshiki Kawabe Junichi Nezu |
| author_sort |
Hiroyasu Muramatsu |
| title |
Novel myostatin-specific antibody enhances muscle strength in muscle disease models |
| title_short |
Novel myostatin-specific antibody enhances muscle strength in muscle disease models |
| title_full |
Novel myostatin-specific antibody enhances muscle strength in muscle disease models |
| title_fullStr |
Novel myostatin-specific antibody enhances muscle strength in muscle disease models |
| title_full_unstemmed |
Novel myostatin-specific antibody enhances muscle strength in muscle disease models |
| title_sort |
novel myostatin-specific antibody enhances muscle strength in muscle disease models |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/f5532204ebd94faaa523b4801829ed1c |
| work_keys_str_mv |
AT hiroyasumuramatsu novelmyostatinspecificantibodyenhancesmusclestrengthinmusclediseasemodels AT taichikuramochi novelmyostatinspecificantibodyenhancesmusclestrengthinmusclediseasemodels AT hitoshikatada novelmyostatinspecificantibodyenhancesmusclestrengthinmusclediseasemodels AT atsunoriueyama novelmyostatinspecificantibodyenhancesmusclestrengthinmusclediseasemodels AT yoshinaoruike novelmyostatinspecificantibodyenhancesmusclestrengthinmusclediseasemodels AT kenohmine novelmyostatinspecificantibodyenhancesmusclestrengthinmusclediseasemodels AT meirishidakawazoe novelmyostatinspecificantibodyenhancesmusclestrengthinmusclediseasemodels AT riemiyanonishizawa novelmyostatinspecificantibodyenhancesmusclestrengthinmusclediseasemodels AT yuichiroshimizu novelmyostatinspecificantibodyenhancesmusclestrengthinmusclediseasemodels AT momokookuda novelmyostatinspecificantibodyenhancesmusclestrengthinmusclediseasemodels AT yujihori novelmyostatinspecificantibodyenhancesmusclestrengthinmusclediseasemodels AT madokahayashi novelmyostatinspecificantibodyenhancesmusclestrengthinmusclediseasemodels AT kentaharaya novelmyostatinspecificantibodyenhancesmusclestrengthinmusclediseasemodels AT nobuhiroban novelmyostatinspecificantibodyenhancesmusclestrengthinmusclediseasemodels AT tatsuyanonaka novelmyostatinspecificantibodyenhancesmusclestrengthinmusclediseasemodels AT masakihonda novelmyostatinspecificantibodyenhancesmusclestrengthinmusclediseasemodels AT hidetomokitamura novelmyostatinspecificantibodyenhancesmusclestrengthinmusclediseasemodels AT kunihirohattori novelmyostatinspecificantibodyenhancesmusclestrengthinmusclediseasemodels AT takehisakitazawa novelmyostatinspecificantibodyenhancesmusclestrengthinmusclediseasemodels AT tomoyukiigawa novelmyostatinspecificantibodyenhancesmusclestrengthinmusclediseasemodels AT yoshikikawabe novelmyostatinspecificantibodyenhancesmusclestrengthinmusclediseasemodels AT junichinezu novelmyostatinspecificantibodyenhancesmusclestrengthinmusclediseasemodels |
| _version_ |
1718396742024560640 |